Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Candida yeasts cause Candidiasis which is a fungal infection commonly found in humans. Infections can occur in the female Genital area "vulvovaginal candidiasis" of which nearly 75% of all adult women have had one "yeast infection" in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur in the hospital intensive care unit (ICU) where it is the fourth most common bloodstream infection (CDC Figures).
This MarketVIEW This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Candida vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for both Recurrent Vulvovaginal Candidiasis (RVVC) and invasive Candidiasis (in the ICU setting) indications. For RVVC indication 3 prevalence scenarios (LO/MID/HI) are included. The product also includes an up-to-date review of latest competitor activity in the field and Candida epidemiology.
THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL
Executive SummaryRVVC TX vaccine: available market ($000s) to 2030, realistic RVVCprevalenceRVVC TX vaccine: available market ($000s) to 2030 by conservative,realistic and optimistic RVVC prevalenceRVVC TX vaccine: available market (000s doses) to 2030Candida ICU PX vaccine: available market ($000s) to 2030Candida ICU PX vaccine: available market (000s doses) to 2030The role of Candida vaccinesCandida ICU PX vaccine: target product profileRVVC TX vaccine: target product profileCandida ICU PX vaccine: model assumptionsRVVC TX vaccine: model assumptionsKey commercial model assumptionsPricingCompetitor landscape: overviewPevion (PEV7)NovaDigm Therapeutics (NDV-3)Vulvovaginal candidiasis: overviewVulvovaginal candidiasis: surveillanceVulvovaginal candidiasis: regional dataVulvovaginal candidiasis: primary care consultationsVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: population based studiesVulvovaginal candidiasis: incidence/prevalence summaryInvasive candidiasis: overviewInvasive candidiasis: national surveillance dataInvasive candidiasis: estimating ICU admissionsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: 50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Charts value (RVVC)
Charts value (ICU)
Charts volume (RVVC and ICU)
Value summary (ICU)
Volume summary (ICU)
Value summary (RVVC)
Volume summary (RVVC)
Model inputs (RVVC)
ICU patients =>
EU other (ICU)
RVVC patients =>
LO/BASE/HI prevalence scenarios
EU other (RVVC)
Source material ?
UK RVVC epi
US ICU epi
Worksheets = >60 interconnected
To order this report:: MarketVIEW: Candida vaccines
Intl: +1 805-652-2626
©2012 PR Newswire. All Rights Reserved.